Common Contracts
2 similar Non-Exclusive License and Material Transfer Agreement contracts by Regeneron Pharmaceuticals Inc
EX-10.1 2 y34395exv10w1.htm EX-10.1: NON-EXCLUSIVE LICENSE AND MATERIAL TRANSFER AGREEMENTNon-Exclusive License and Material Transfer Agreement • May 5th, 2020 • New York
Exhibit 10.1 NON-EXCLUSIVE LICENSE AND MATERIAL TRANSFER AGREEMENT This Non-Exclusive License and Material Transfer Agreement (“Agreement”) is entered into with an effective date as of March 30, 2007 (the “Effective Date”), by and between Astellas Pharma Inc., a Japanese company with a principal place of business located at 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan (“Company”), and Regeneron Pharmaceuticals, Inc. (“Regeneron”), a New York corporation, with a principal place of business located at 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707. WITNESSETH WHEREAS, Regeneron has developed antibody technology, including genetically modified mice and related know-how, useful to generate human monoclonal antibodies; WHEREAS, Regeneron owns certain patents and patent applications covering its human antibody technology; WHEREAS, Company desires to obtain certain non-exclusive licenses under Regeneron Technology (as defined below), including the right to commerciali
NON-EXCLUSIVE LICENSE AND MATERIAL TRANSFER AGREEMENTNon-Exclusive License and Material Transfer Agreement • May 4th, 2007 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Non-Exclusive License and Material Transfer Agreement (“Agreement”) is entered into with an effective date as of March 30, 2007 (the “Effective Date”), by and between Astellas Pharma Inc., a Japanese company with a principal place of business located at 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan (“Company”), and Regeneron Pharmaceuticals, Inc. (“Regeneron”), a New York corporation, with a principal place of business located at 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707.
